We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
With the sustained investment in China's pharmaceutical industry and the growing attraction of China's pharmaceutical market to global innovative drugs, more projects of innovative drugs have added the listing in China as a necessary part.
According to the agreement, WuXi STA will become the preferred CDMO partner and provide Coherent Biopharma with integrated CMC services to accelerate its present and future drug candidates